** Shares of drug developer Biohaven Ltd BHVN.N fall 14.4% to $39.02 premarket
** BHVN says its experimental drug, taldefgrobep alfa, did not meet the main goal of improving muscle function in patients with a rare neuromuscular disorder called spinal muscular atrophy in a late-stage study
** Taldefgrobep alfa is designed to block myostatin, a protein that limits muscle growth, which helps increase muscle mass and improve muscle function
** However, the drug showed positive effects on body composition, such as reducing fat mass, supporting its potential as an obesity treatment, co says
** As of last close, stock has risen 6.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。